Jiangsu Rec-Biotechnology Co., Ltd.
5 clinical trials · Sponsor
◉ Watch Jiangsu Rec-Biotechnology Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell) (NCT05769049) | Jiangsu Rec-Biotechnology Co., Ltd. | 2023-02-09 |
| Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov) (NCT05398848) | Jiangsu Rec-Biotechnology Co., Ltd. | 2022-10-31 |
| Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV) (NCT05323435) | Jiangsu Rec-Biotechnology Co., Ltd. | 2022-05-30 |
| Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (NCT05084989) | Jiangsu Rec-Biotechnology Co., Ltd. | 2022-01-31 |
| Safety, Reactogenicity and Immunogenicity Study of ReCOV (NCT04818801) | Jiangsu Rec-Biotechnology Co., Ltd. | 2021-06-18 |
Track Jiangsu Rec-Biotechnology Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.